Equilliumbio.com

Site Inspections

Overview & More informations

EquilibriumBio is a biotechnology company that is developing a novel class of cancer therapies based on the concept of synthetic lethality. The company's lead product candidate, EQB-110, is a small molecule inhibitor of the enzyme CHK1. CHK1 is a key regulator of the cell cycle and is essential for the survival of cancer cells. By inhibiting CHK1, EQB-110 causes cancer cells to undergo apoptosis, or programmed cell death.

EquilibriumBio was founded in 2016 by a team of scientists from the University of California, Berkeley. The company is headquartered in San Francisco, California. EquilibriumBio has raised a total of $68 million in funding from investors including ARCH Venture Partners, Khosla Ventures, and MPM Capital.

EquilibriumBio's technology is based on the concept of synthetic lethality. Synthetic lethality is a phenomenon that occurs when two genes are mutated in a cell, and the cell is unable to survive. In the case of EQB-110, the molecule is designed to target a specific gene mutation that is common in cancer cells. By inhibiting this gene, EQB-110 causes cancer cells to die, while leaving healthy cells unharmed.

EquilibriumBio's technology has the potential to revolutionize the treatment of cancer. By targeting specific gene mutations, EQB-110 can be used to treat a wide range of cancers, including those that are currently difficult to treat. EquilibriumBio is currently conducting clinical trials of EQB-110 in patients with advanced cancer. The company expects to file for regulatory approval of EQB-110 in 2023.

Domains Expiration Date Updated